Actively Recruiting
Holmium-166 Transarterial Radioembolization for the Treatment of Hepatocellular Carcinoma
Led by Universitair Ziekenhuis Brussel · Updated on 2025-03-12
100
Participants Needed
1
Research Sites
52 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
This study aims to evaluate the effectiveness and safety of Holmium-166 (Ho-166) transarterial radioembolization (TARE) for treating patients with locally advanced hepatocellular carcinoma (HCC), a common type of liver cancer. HCC is often linked to conditions like liver cirrhosis and viral hepatitis, with a poor prognosis for advanced stages. TARE involves delivering radioactive particles directly to liver tumors, sparing healthy tissue and providing targeted radiation. This study will include patients diagnosed with HCC who have received Holmium-166 TARE treatment between January 2010 and December 2024. Researchers will look at patient and tumor characteristics, side effects, how well the treatment works, and survival outcomes. The goal is to determine whether Holmium-166 TARE is a safe and effective treatment option for people with locally advanced HCC. The findings will help doctors better understand how this therapy can be used to treat liver cancer and whether it can improve survival rates for patients with this challenging disease.
CONDITIONS
Official Title
Holmium-166 Transarterial Radioembolization for the Treatment of Hepatocellular Carcinoma
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Aged 18 years or older
- Diagnosed with locally advanced hepatocellular carcinoma without extra-hepatic metastases
- HCC not suitable for surgical resection or percutaneous radiofrequency ablation
- Considered suitable for Holmium-166 TARE treatment by investigator and tumor board
- ECOG performance status 0 to 2
- Child-Pugh class A or B liver function
- Tumor response evaluable with mRECIST criteria during follow-up
You will not qualify if you...
- Prior treatment with systemic therapy or hepatic radiation therapy for HCC
- Currently enrolled in clinical studies with investigational therapeutic drugs
- Presence of metastatic disease
- Concurrent other cancers
- Active contraindications to angiography or selective catheterization (e.g., severe vascular disease, bleeding disorders)
- Uncontrolled or severe comorbidities with limited life expectancy (e.g., active infection, heart failure)
- History of or known allergies to compounds used in treatment
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
UZ Brussel
Brussels, Belgium
Actively Recruiting
Research Team
H
Helena Degroote
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
0
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here